Navigation Links
TELITHROMYCIN - the proven effective new drug for cap

Community acquired pneumonia other wise known as CAP has been a therapeutic challenge to most of the practising physicians. This is mainly due to the growing resistance of the bacteria causing them to the available antibiotics.

Telithromycin (Ketek), a new ketolide antibiotic, is highly effective in treating patients with pneumococcal bacteraemia associated with community-acquired pneumonia (CAP). This is a breakthrough in the field of anti microbials as pneumococcal resistance is on the rage. Dr. Thomas M. File, Jr., of Northeastern Ohio University of Medicine, Rootstown, commented that, "Currently clinicians who perceive their patients to be at risk for infection with resistant pathogens are relying on one or two classes of antimicrobials. This results in increased pressure on those classes ", and this infact is responsible for the resistance strains of this group of bacteria.

The efficacy of the drug was assessed by five clinical trials and clinical and biological outcomes was noted. Blood samples were taken before and after the therapy for both aerobic and anaerobic culture. It was found that, the overall clinical cure rate with telithromycin was 89.5% after 7 to 11 days of therapy.

Telithromycin has recently been approved by the US Food and Drug Administration for the treatment of CAP, acute bacterial exacerbation of chronic bronchitis (ABECB), and acute bacterial sinusitis (ABS) and is marketed by Aventis Pharma.
'"/>




Page: 1

Related medicine news :

1. Partial-Breast Irradiation an Unproven Therapy
2. New drug proven to tackle Type 2 Diabetes
3. Morning after pill effective up to five days after having unprotected sex
4. Distraction therapy found very effective in postoperative patients
5. Digital mammography proves effective
6. Treatment for pre-menstrual syndrome is ineffective
7. Cost-effective antibiotics for sinusitis treatment
8. An effective way to treat angina
9. Fluoride proves effective against fractures
10. Meningitis C vaccine a cost-effective success
11. An effective drug for lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2016)... ... , ... David J. Dykeman , Ginger Pigott , and ... at DeviceTalks West, Dec. 12, 2016, at the Fairmont Newport Beach in California. Greenberg ... global Life Sciences & Medical Technology Group have been featured speakers at every DeviceTalks ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... 10.2 version gives development continuity to its innovative Unified Instance Manager architecture, ... capacity. In addition, this new version optimizes the unattended auto-dialing system without ...
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased to ... convenient service for Texas, they are expanding their presence in Dallas. One of the ... that will bring new jobs to the Dallas and Forth Worth market. STAT takes ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... and the Affordable Care Act. Dr. Botelho advocates for the mass media launching ... movement gives people ongoing opportunities to share their unfortunate experiences; such a movement ...
(Date:12/8/2016)... ... December 08, 2016 , ... The ... from offices headquartered in Hamilton County, is embarking on a charity drive with ... in finding new homes for orphaned or neglected senior dogs in the Cincinnati ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 8, 2016 Australia Glaucoma Surgery Devices ... new report, "Australia Glaucoma Surgery Devices Market Outlook ... Australia Glaucoma Surgery Devices market. The report provides ... units) and average prices (USD) within market segement ... provides company shares and distribution shares data for ...
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... to grow in 2017-2023. Various reasons for growth of ... population, higher incidences of chronic diseases, high recovery cost ... aid services. Medical lifting sling refers to an ... limited mobility. These slings connect to the lift and ...
(Date:12/8/2016)... Dec. 8, 2016  Eli Lilly and Company (NYSE: ... its phase 3 EXPEDITION3 trial at the 9 th ... previously disclosed, solanezumab did not meet the primary endpoint ... initiated in people with mild dementia due to Alzheimer,s ... for solanezumab for the treatment of mild dementia due ...
Breaking Medicine Technology: